Gilead Sciences (GILD) used the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026, to walk analysts through an expanded pipeline spanning HIV prevention, cell therapies, and inflammation programs, signaling a continued push to reduce dependency on any single therapeutic area.
The company's stock was trading at $145.70, down 0.64% at the time of the event. Gilead noted it has raised its dividend for 11 consecutive years, yielding 2.24%, as it balances growth investments with shareholder returns.
In HIV, Gilead is building a range of prevention options. The once-weekly oral lenacapavir filing is expected to receive FDA approval in Q1 2027, while once-yearly intramuscular lenacapavir data is anticipated in 2027. Current market penetration remains limited: approximately 500,000 people are on pre-exposure prophylaxis (PrEP), compared with an estimated 2.2 million eligible individuals identified by the CDC — roughly 23% penetration. Chief Medical Officer Dr. Dietmar Berger said the company is developing oral, injectable, subcutaneous, and intramuscular formats to address distinct patient preferences, noting strong interest at clinical sites in the "vaccine-like" convenience of the annual injection.
GS-3242, a long-acting integrase inhibitor, currently provides about four months of coverage, with combination data expected by end of 2026.
In oncology, Gilead reported that more than 400 patients have been treated with anito-cel, its CAR-T therapy from Arcellx, across datasets with median observation periods of 15 months and up to 38 months. Berger said no cases of delayed neurotoxicity, Parkinsonism, Guillain-Barré syndrome, or enterocolitis have been observed — side effects seen at rates of up to 10% with some competitor products — noting the critical window for such events is within the first 100 days. Anito-cel is expected to approach launch in fourth-line and later multiple myeloma in late 2026.
Gilead also highlighted its Tubulis antibody-drug conjugate technology, particularly TUB-040, which showed a 60% objective response rate in platinum-resistant ovarian cancer in an unselected population. About 85% of ovarian cancer patients express the NaPi2b target. The P5 linker technology produces a stable linkage with less free payload in circulation, while the Alco5 platform allows payload variability beyond traditional topoisomerase inhibitors.
In inflammation and immunology, Gilead expects multiple data readouts in the second half of 2026, including for envistidagrast, an oral alpha-4 beta-7 integrin inhibitor, and an IRAK4 inhibitor in cutaneous lupus. OM336, a BCMA T-cell engager, is planned for Phase III development in immune thrombocytopenia and autoimmune hemolytic anemia in 2027.
Berger acknowledged that Gilead now needs to "prioritize" its programs, calling that discipline "a good thing." The management team, many of whom joined the company seven years ago, is steering what Berger described as a deliberate narrowing of focus across an increasingly broad portfolio.
